Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of inhaled budesonide on the incidence and severity of Acute Mountain Sickness at 4559 m
2016-000160-42Phase 2Completed
- Sponsor
- DGAI
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of budesonide in acute mountain sickness (AMS) and high altitude illness, sponsored by DGAI. Primary endpoint: Incidence of Acute Mountain Sickness. Started Mar 2016; status: completed.
02
Drugs
budesonide
03
Conditions
acute mountain sickness (AMS)high altitude illness
Beyond the preview
Go deeper on 2016-000160-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000160-42.